₹33,000.00 Original price was: ₹33,000.00.₹22,000.00Current price is: ₹22,000.00.
A comprehensive genetic screening test for early detection of cancer-related risks.
37 in stock
Many of the cancers it covers lack standard screening protocols, making early detection difficult.
CancerSpot provides a non-invasive, accessible solution, enabling early identification and timely medical intervention when treatment outcomes are most effective.
Achieves 81% sensitivity at 97% specificity across 10 cancer types.
Detects cancer signals with 79% sensitivity (at 97% specificity) for Stage I–II cancers.
A single blood draw, no radiation, no hospital procedure.
Screens for 10 major cancers: colorectal, stomach, esophageal, liver, gallbladder, pancreatic, lung, breast, cervical, and ovarian.
Validated on Indian cohorts and proven consistent across ethnicities.
Colorectal, Lung, Ovarian, Breast, Stomach, Cervical, Gall Bladder, Liver, Pancreas, Esophageal
Find out through a one-on-one genetic counselling session.
Strand Life Sciences is India’s pioneering genomics company with over 25 years of research and is a Reliance portfolio company.
Yes. The test screens for genetic changes associated with early-stage cancers, helping you take preventive action before symptoms develop.
Anyone interested in proactive cancer prevention, especially those with a family history of cancer or planning for long-term health.
Your genetic counsellor will guide you on follow-up screenings, lifestyle adjustments, and preventive strategies tailored to your risk profile.
With Next-Generation Sequencing and CAP/NABL/ISO accreditation, the test provides highly accurate detection of relevant genetic markers.
CancerSpot is a screening test, not a diagnostic tool.
It cannot confirm or rule out cancer presence with complete certainty. A positive signal indicates the need for further diagnostic follow-up as advised by your physician.
₹24,000.00 Original price was: ₹24,000.00.₹15,000.00Current price is: ₹15,000.00.
₹7,500.00